. 2021 May 6;4(5):e218065. doi: 10.1001/jamanetworkopen.2021.8065

Table 1. Basic Parameters Input to the Model and the Ranges of the Sensitivity Analyses^a.

Parameter	Baseline value	Lower limit	Upper limit	Distribution	Source
Lognormal OS survival model of nivolumab	μ = 1.9092; σ = 1.3333	ND	ND	ND	Model fitting
Log-logistic PFS survival model of pembrolizumab	γ = 1.6809; λ = 0.3649	ND	ND	ND	Model fitting
HR for OS (nivolumab vs pembrolizumab)	0.86	0.63	1.17	Lognormal	Network meta-analysis
HR for PFS (nivolumab vs pembrolizumab)	0.91	0.66	1.25	Lognormal	Network meta-analysis
Rate of treatment discontinuation
Pembrolizumab group	0.06	0.045^b	0.075^b	Beta	Cohen et al,⁷ 2019
Nivolumab group	0.042	0.032^b	0.053^b	Beta	Ferris et al,⁶ 2019
Drug cost (per month), $
Pembrolizumab	13 403.73	10 052.80^b	16 754.67^b	Gamma	CMS³¹
Nivolumab	11 828.04	8871.03^b	14 785.05^b	Gamma	CMS³¹
Cetuximab
The first cycle	13 519.76	10 139.82^b	16 899.70^b	Gamma	CMS³¹
The ensuing cycle	11 756.32	8817.24^b	14 695.40^b	Gamma	CMS³¹
Methotrexate	14.88	11.16^b	18.60^b	Gamma	CMS³¹
Docetaxel	251.29	188.47^b	314.11^b	Gamma	CMS³¹
Paclitaxel	82.14	61.61^b	102.68^b	Gamma	CMS³¹
Fluorouracil	30.00	22.50^b	37.50^b	Gamma	CMS³¹
Carboplatin	39.45	29.59^b	49.31^b	Gamma	CMS³¹
Cisplatin	47.84	35.88^b	59.80^b	Gamma	CMS³¹
Afatinib	13 104.00	9828.00^b	16 380.00^b	Gamma	UpToDate³²^c
Drug administration costs, $
Chemotherapy infusion
First hour	142.55	122.39	206.68	Gamma	CPT code 96413³³
Additional hour	30.68	27.00	43.02	Gamma	CPT code 96415³³
Immunohistochemical test	107.19	95.15	151.82	Gamma	CPT code 88342³³
Follow-up cost per month	1443.16	1082.37^b	1803.95^b	Gamma	CPT code 78816³⁴
Best supportive care cost per month	4409.00	2050.00	6861.00	Gamma	Ward et al,¹⁹ 2017; Enomoto et al,³⁵ 2015; Gourin et al,³⁶ 2014
Terminal care cost	10 561.00	7920.75^b	13 201.25^b	Gamma	Enomoto et al,³⁵ 2015
SAE management cost, $^d
Pembrolizumab group	611.80	289.66	700.52	Gamma	Haddad et al,¹¹ 2020; Ward et al,¹⁹ 2017; Wong et al,³⁷ 2018; Burudpakdee et al,³⁸ 2012; Hagiwara et al,³⁹ 2013; Swallow et al,⁴⁰ 2018; Wan et al,⁴¹ 2019
Nivolumab group	902.60	417.87	1206.83	Gamma	Haddad et al,¹¹ 2020; Ward et al,¹⁹ 2017; Wong et al,³⁷ 2018; Burudpakdee et al,³⁸ 2012; Hagiwara et al,³⁹ 2013; Swallow et al,⁴⁰ 2018; Wan et al,⁴¹ 2019
Health utilities^e
Progression-free survival	0.805	0.786	0.824	Beta	Haddad et al,¹¹ 2020
Progressed disease	0.746	0.716	0.775	Beta	Haddad et al,¹¹ 2020
SAE utility toll^f
Pembrolizumab group	0.007	0.004	0.010	Beta	Haddad et al,¹¹ 2020; Kohn et al,²⁴ 2017; Nafees et al,²⁵ 2017; Lloyd et al,²⁶ 2008; Zargar et al,²⁷ 2018; Tam et al,²⁸ 2013; Lee et al,²⁹ 2013; Beusterien et al,³⁰ 2010
Nivolumab group	0.013	0.007	0.018	Beta	Haddad et al,¹¹ 2020; Kohn et al,²⁴ 2017; Nafees et al,²⁵ 2017; Lloyd et al,²⁶ 2008; Zargar et al,²⁷ 2018; Tam et al,²⁸ 2013; Lee et al,²⁹ 2013; Beusterien et al,³⁰ 2010
Rate of wastage of nivolumab	0.061	0.046^b	0.076^b	Beta	Fukudo et al,⁴² 2020
Body surface area, m²	1.86	1.40^b	2.33^b	Normal	Ward et al,¹⁹ 2017
Body weight, kg	70	50	90	Normal	Ward et al,¹⁹ 2017
Discount rate	0.03	0	0.08	Uniform	Sanders et al,¹⁵ 2016
Time horizon, mo	180	60	360	Uniform	Tringale et al,⁴³ 2018

Abbreviations: CMS, Centers for Medicare & Medicaid Services; CPT, Current Procedural Terminology; HR, hazard ratio; ND, not determined; OS, overall survival; PFS, progression-free survival; SAE, severe adverse event.

^{^a}

For additional details, see eTable 4 in the Supplement.

^{^b}

Variance of plus or minus 25% from baseline values.

^{^c}

Adjusted with the same discount of the price for pembrolizumab between UpToDate and CMS.

^{^d}

The mean cost of toxicity weighted by the frequency of occurrence.

^{^e}

The health utilities are values that vary between 0 and 1 and have no units.

^{^f}

The mean utility toll of toxicity weighted by the frequency of occurrence.

Table 1. Basic Parameters Input to the Model and the Ranges of the Sensitivity Analysesa.

Table 1. Basic Parameters Input to the Model and the Ranges of the Sensitivity Analyses^a.